000110778 001__ 110778
000110778 005__ 20240319080947.0
000110778 0247_ $$2doi$$a10.1038/s41416-021-01610-8
000110778 0248_ $$2sideral$$a126034
000110778 037__ $$aART-2022-126034
000110778 041__ $$aeng
000110778 100__ $$aRamirez-Garrastacho, Manuel
000110778 245__ $$aExtracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research
000110778 260__ $$c2022
000110778 5060_ $$aAccess copy available to the general public$$fUnrestricted
000110778 5203_ $$aProstate cancer is a global cancer burden and considerable effort has been made through the years to identify biomarkers for the disease. Approximately a decade ago, the potential of analysing extracellular vesicles in liquid biopsies started to be envisaged. This was the beginning of a new exciting area of research investigating the rich molecular treasure found in extracellular vesicles to identify biomarkers for a variety of diseases. Vesicles released from prostate cancer cells and cells of the tumour microenvironment carry molecular information about the disease that can be analysed in several biological fluids. Numerous studies document the interest of researchers in this field of research. However, methodological issues such as the isolation of vesicles have been challenging. Remarkably, novel technologies, including those based on nanotechnology, show promise for the further development and clinical use of extracellular vesicles as liquid biomarkers. Development of biomarkers is a long and complicated process, and there are still not many biomarkers based on extracellular vesicles in clinical use. However, the knowledge acquired during the last decade constitutes a solid basis for the future development of liquid biopsy tests for prostate cancer. These are urgently needed to bring prostate cancer treatment to the next level in precision medicine.
000110778 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000110778 590__ $$a8.8$$b2022
000110778 592__ $$a2.867$$b2022
000110778 591__ $$aONCOLOGY$$b36 / 241 = 0.149$$c2022$$dQ1$$eT1
000110778 593__ $$aOncology$$c2022$$dQ1
000110778 593__ $$aCancer Research$$c2022$$dQ1
000110778 594__ $$a14.1$$b2022
000110778 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000110778 700__ $$aBajo-Santos, Cristina
000110778 700__ $$aLine, Aija
000110778 700__ $$aMartens-Uzunova, Elena S.
000110778 700__ $$0(orcid)0000-0003-1081-8482$$aMartínez de la Fuente, Jesús
000110778 700__ $$0(orcid)0000-0002-2861-2469$$aMoros, María
000110778 700__ $$aSoekmadji, Carolina
000110778 700__ $$aTasken, Kristin Austlid
000110778 700__ $$aLlorente, Alicia
000110778 773__ $$g126 (2022), 331–350$$pBr. J. Cancer$$tBRITISH JOURNAL OF CANCER$$x0007-0920
000110778 8564_ $$s1706578$$uhttps://zaguan.unizar.es/record/110778/files/texto_completo.pdf$$yVersión publicada
000110778 8564_ $$s2849754$$uhttps://zaguan.unizar.es/record/110778/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000110778 909CO $$ooai:zaguan.unizar.es:110778$$particulos$$pdriver
000110778 951__ $$a2024-03-18-12:43:56
000110778 980__ $$aARTICLE